Hydrazones, hydrazines, semicarbazones and thiosemicarbazones derived
from pyridyl ketones as anticonvulsant drugs and excitatory amino acid
antagonists
    1.
    发明授权
    Hydrazones, hydrazines, semicarbazones and thiosemicarbazones derived from pyridyl ketones as anticonvulsant drugs and excitatory amino acid antagonists 失效
    衍生自吡啶酮的腙,肼,缩氨基脲和缩氨基硫脲作为抗惊厥药物和兴奋性氨基酸拮抗剂

    公开(公告)号:US5942527A

    公开(公告)日:1999-08-24

    申请号:US917925

    申请日:1997-08-27

    CPC分类号: C07D213/53

    摘要: Pharmaceutical compositions comprise as the active ingredient potent orally active, nonneurotoxic anticonvulsant compounds that are highly effective in the MES animal model and are excitatory amino acid antagonists, and that are selected from the groups of hydrazones, hydrazines and semicarbazones consisting of those of the formulae: ##STR1## wherein R.sup.1 is 4-pyridyl or 3-pyridyl, R.sup.2 is methyl, ethyl or phenyl, R.sup.3 is 3,4-dichloro, p-chloro or m-chloro and R.sup.4 is oxygen. The compositions are administered to mammals in an amount to provide a dosage amount ranging from about 10 mg/kg to 200 mg/kg of body weight.

    摘要翻译: 药物组合物包含作为活性成分的有效的口服活性的非神经毒性抗惊厥化合物,其在MES动物模型中是高度有效的,并且是兴奋性氨基酸拮抗剂,并且选自由以下结构式组成的腙,肼和缩氨基脲类: 其中R1是4-吡啶基或3-吡啶基,R2是甲基,乙基或苯基,R3是3,4-二氯,对氯或间氯,R4是氧。 组合物以提供约10mg / kg至200mg / kg体重的剂量的量施用于哺乳动物。

    &Dgr;2-1,2,3-TRIAZOLINE ANTICONVULSANTS AND THEIR ACTIVE METABOLITE ANALOGUES, THE AMINOALKYLPYRIDINES, ARE EXCITATORY AMINO ACID ANTAGONISTS AND ANTIISCHEMIC AGENTS, USEFUL IN THE TREATMENT OF CEREBRAL ISCHEMIA RESULTING FROM STROKE
    2.
    发明授权
    &Dgr;2-1,2,3-TRIAZOLINE ANTICONVULSANTS AND THEIR ACTIVE METABOLITE ANALOGUES, THE AMINOALKYLPYRIDINES, ARE EXCITATORY AMINO ACID ANTAGONISTS AND ANTIISCHEMIC AGENTS, USEFUL IN THE TREATMENT OF CEREBRAL ISCHEMIA RESULTING FROM STROKE 有权
    Delta2-1,2,3-TRIAZOLINE ANTICVULSANTS及其活性代谢物类似物,氨基腺嘌呤,是激素氨基酸拮抗剂和抗细胞剂,用于治疗从STROKE发生的胚胎间质

    公开(公告)号:US06638954B2

    公开(公告)日:2003-10-28

    申请号:US09985318

    申请日:2001-11-02

    申请人: Pankaja K. Kadaba

    发明人: Pankaja K. Kadaba

    IPC分类号: A61K3144

    摘要: Pharmaceutical compositions comprise as the active ingredient, nonneurotixic antiischemic compounds that are highly effective by the intraperitoneal route, and that are excitatory amino acid and NMDA/sigma receptor antagonists and are selected from the group consisting of those of the formulae, wherein R2 is 4-pyridyl, 3-pyridyl, or 2-oxo-1-pyrrolidino and R1 is 3,4- or 3,5-dichloro, p- or m-chloro, p- or m-bromo, p- or m-fluoro, p- or m-trifluoromethyl, p-methyl, p-methoxy, or hydrogen, and those of the formulae, wherein R2 is 4-pyridyl or 3-pyridyl, R3 is hydrogen, methyl or ethyl and R1 is 3,4- or 3,5-dichloro, p- or m-chloro, p- or m-bromo, p- or m-fluoro, p- or m-trifluoromethyl, p-methyl, p-methoxy or hydrogen.

    摘要翻译: 药物组合物包含通过腹膜内途径高度有效的兴奋性氨基酸和NMDA /σ受体拮抗剂作为活性成分的非神经性抗缺血化合物,并且选自下式的那些:其中R 2, 是4-吡啶基,3-吡啶基或2-氧代-1-吡咯烷子基,R 1是3,4-或3,5-二氯,对或间氯,对或间溴,对 - 或m-氟,对或间三氟甲基,对甲基,对甲氧基或氢,以及下式的那些,其中R 2是4-吡啶基或3-吡啶基,R 3是氢,甲基或乙基 对 - 或间 - 氯,对或间溴,对或间氟,对或间三氟甲基,对甲基,p - 甲氧基或氢。

    Triazoline anticonvulsant compounds and compositions
    3.
    发明授权
    Triazoline anticonvulsant compounds and compositions 失效
    三唑啉抗惊厥化合物和组合物

    公开(公告)号:US4689334A

    公开(公告)日:1987-08-25

    申请号:US856782

    申请日:1986-04-17

    申请人: Pankaja K. Kadaba

    发明人: Pankaja K. Kadaba

    CPC分类号: C07D401/04 C07D249/06

    摘要: Anticonvulsant compositions comprise as the active ingredient a compound selected from the group consisting of those of the formulae: ##STR1## wherein R.sub.1 is o-chlorophenyl, o-nitrophenyl, 2,4- or 2,6-dichlorophenyl, 4-pyridyl, 3-pyridyl, 2-pyridyl, or 2-quinolyl, and R.sub.2 is hydrogen, m- or p-trifluoromethyl, m-chloro-p-fluoro, p-methyl, p-ethyl, m- or p-chloro, m-nitro, p-bromo, p-fluoro, or p-COOR.sub.3, wherein R.sub.3 is lower alkyl of 1 to 4 carbon atoms. The compositions are administered to mammals in an amount to provide a dosage amount ranging from about 30 mg/kg to 300 mg/kg.

    摘要翻译: 抗惊厥药组合物包含选自下组的化合物作为活性成分:其中R1是邻氯苯基,邻硝基苯基,2,4-或2,6-二氯苯基,4-吡啶基,3 吡啶基,2-吡啶基或2-喹啉基,R 2为氢,间或对三氟甲基,间氯代对氟,对甲基,对乙基,间或对氯,间硝基 ,对溴,对氟或对COOR 3,其中R 3是1至4个碳原子的低级烷基。 将组合物以提供约30mg / kg至300mg / kg的剂量的量施用于哺乳动物。

    Aryl substituted 1H-4,5-dihydro-1,2,3-triazoles as anticonvulsants
    4.
    发明授权
    Aryl substituted 1H-4,5-dihydro-1,2,3-triazoles as anticonvulsants 失效
    芳基取代的1H-4,5-二氢-1,2,3-三唑作为抗惊厥药

    公开(公告)号:US4618681A

    公开(公告)日:1986-10-21

    申请号:US629554

    申请日:1984-07-10

    申请人: Pankaja K. Kadaba

    发明人: Pankaja K. Kadaba

    IPC分类号: C07D249/06 C07D401/04

    CPC分类号: C07D401/04 C07D249/06

    摘要: Anticonvulsant compositions comprise as the active ingredient a compound selected from the group consisting of those of the formulae: ##STR1## wherein R.sub.1 is o-chlorophenyl, o-nitrophenyl, 2,4- or 2,6-dichlorophenyl, 4-pyridyl, 3-pyridyl, 2-pyridyl, or 2-quinolyl, and R.sub.2 is hydrogen, m- or p-trifluoromethyl, m-chloro-p-fluoro, p-methyl, p-ethyl, m- or p-chloro, m-nitro, p-bromo, p-fluoro, or p-COOR.sub.3, wherein R.sub.3 is lower alkyl of 1 to 4 carbon atoms. The compositions are administered to mammals in an amount to provide a dosage amount ranging from about 30 mg/kg to 300 mg/kg.

    摘要翻译: 抗惊厥药组合物包含选自下组的化合物作为活性成分:其中R1是邻氯苯基,邻硝基苯基,2,4-或2,6-二氯苯基,4-吡啶基,3 吡啶基,2-吡啶基或2-喹啉基,R 2为氢,间或对三氟甲基,间氯代对氟,对甲基,对乙基,间或对氯,间硝基 ,对溴,对氟或对COOR 3,其中R 3是1至4个碳原子的低级烷基。 将组合物以提供约30mg / kg至300mg / kg的剂量的量施用于哺乳动物。

    1,2,3-triazole anticonvulsant drugs
    5.
    发明授权
    1,2,3-triazole anticonvulsant drugs 失效
    1,2,3-三唑抗惊厥药

    公开(公告)号:US4610994A

    公开(公告)日:1986-09-09

    申请号:US604026

    申请日:1984-04-26

    申请人: Pankaja K. Kadaba

    发明人: Pankaja K. Kadaba

    CPC分类号: C07D401/04 C07D249/06

    摘要: Anticonvulsant compositions comprise as the active ingredient a compound selected from the group consisting of those of the formulae: ##STR1## wherein R.sub.1 is phenyl, 4-pyridyl, 3-pyridyl, or 2-pyridyl, and R.sub.2 is hydrogen, m- or p-methyl, p-methoxy, m- or p-chloro, m- or p-bromo, m- or p-fluoro, m- or p-trifluoromethyl, 3,4-dichloro or 3,5-dichloro. The compositions are administered to mammals in an amount to provide a dosage amount ranging from about 25 mg/kg to 300 mg/kg.

    摘要翻译: 抗惊厥药组合物包含选自下组的化合物作为活性成分:其中R1是苯基,4-吡啶基,3-吡啶基或2-吡啶基,R2是氢,m-或p 甲基,对甲氧基,间或对氯,间或对溴,间或对氟,间或对三氟甲基,3,4-二氯或3,5-二氯。 组合物以提供约25mg / kg至300mg / kg的剂量的量施用于哺乳动物。

    Triazoline anticonvulsant drugs
    6.
    发明授权
    Triazoline anticonvulsant drugs 失效
    三唑啉抗惊厥药

    公开(公告)号:US4511572A

    公开(公告)日:1985-04-16

    申请号:US476792

    申请日:1983-03-18

    申请人: Pankaja K. Kadaba

    发明人: Pankaja K. Kadaba

    CPC分类号: C07D401/04 C07D249/06

    摘要: Anticonvulsant compositions comprise as the active ingredient a compound selected from the group consisting of those of the formulae: ##STR1## wherein R.sub.1 is o-chlorophenyl, o-nitrophenyl, 2,4- or 2,6-dichlorophenyl, 4-pyridyl, 2-pyridyl, or 2-quinolyl, and R.sub.2 is hydrogen, m- or p-trifluoromethyl, p-methyl, p-ethyl, m- or p-chloro, m-nitro, p-bromo, p-fluoro or p-COOR.sub.3 wherein R.sub.3 is lower alkyl of 1 to 4 carbon atoms. The compositions are administered to mammals in an amount to provide a dosage amount ranging from about 30 mg/kg to 300 mg/kg.

    摘要翻译: 抗惊厥药组合物包含选自下组的化合物作为活性成分:其中R1是邻氯苯基,邻硝基苯基,2,4-或2,6-二氯苯基,4-吡啶基,2 - 吡啶基或2-喹啉基,R 2是氢,间或对三氟甲基,对甲基,对乙基,间或对氯,间硝基,对溴,对氟或对COOR 3 其中R 3是1至4个碳原子的低级烷基。 将组合物以提供约30mg / kg至300mg / kg的剂量的量施用于哺乳动物。

    Optical resolution of racemic aminoalkylpyridine anticonvulsants and (+)
aminoalkylpyridine enantiomers as highly potent orally effective
anticonvulsant drugs and excitatory amino acid antagonists
    7.
    发明授权
    Optical resolution of racemic aminoalkylpyridine anticonvulsants and (+) aminoalkylpyridine enantiomers as highly potent orally effective anticonvulsant drugs and excitatory amino acid antagonists 失效
    外消旋氨基烷基吡啶抗惊厥药和(+)氨基烷基吡啶对映异构体作为高效口服有效的抗惊厥药物和兴奋性氨基酸拮抗剂的光学拆分

    公开(公告)号:US6083964A

    公开(公告)日:2000-07-04

    申请号:US251353

    申请日:1999-02-17

    申请人: Pankaja K. Kadaba

    发明人: Pankaja K. Kadaba

    CPC分类号: C07D213/38

    摘要: A specific method of optical resolution using dibenzoyltartrate (DBTA) is described for the preparation of six new (+) and (-) enantiomers each of six racemic aminoalkylpyridines. The (+) enantiomers are potent orally active, non-neurotoxic anticonvulsant compounds that are highly effective in the MES test and the hippocampal kindled rat model with no activity in the sc Met test and that significantly raise seizure threshold in the i.v. Metrazol seizure threshold screen. Pharmaceutical compositions, to treat convulsive disorders, comprising as the active ingredient one of the above (+) or (-) aminoalkylpyridine enantiomers, that are selected from the groups of enantiomers consisting of those of the formulae: ##STR1## wherein R.sup.1 is methyl or ethyl and R.sup.2 is 3,4-dichloro, p- or m-chloro or p-bromo. The compositions are administered to mammals in an amount to provide a dosage amount ranging from about 10 mg/kg to 200 mg/kg of body weight.

    摘要翻译: 描述了使用二苯甲酰酒石酸盐(DBTA)的具体的光学拆分方法,用于制备六种外消旋氨基烷基吡啶中的六种新的(+)和( - )对映异构体。 (+)对映异构体是有效的口服活性,非神经毒性抗惊厥化合物,在MES试验和海马点燃的大鼠模型中非常有效,在sc Met检测中无活性,并显着提高i.v中的癫痫发作阈值。 咪唑缉获阈值屏。 药物组合物,用于治疗惊厥性疾病,其包含作为上述(+)或( - )氨基烷基吡啶对映异构体之一的活性成分,其选自下式的那些对映异构体:其中R 1为甲基或乙基,R 2为 是3,4-二氯,对或间氯或对溴。 组合物以提供约10mg / kg至200mg / kg体重的剂量的量施用于哺乳动物。

    Aminoalkylpyridine compounds which are useful as anitconvulsant drugs,
excitatory amino acid inhibitors and NMDA sigma receptor antagonists
    8.
    发明授权
    Aminoalkylpyridine compounds which are useful as anitconvulsant drugs, excitatory amino acid inhibitors and NMDA sigma receptor antagonists 失效
    可用作惊厥药物,兴奋性氨基酸抑制剂和NMDA西格玛受体拮抗剂的氨基烷基吡啶化合物

    公开(公告)号:US5648369A

    公开(公告)日:1997-07-15

    申请号:US793725

    申请日:1991-11-20

    申请人: Pankaja K. Kadaba

    发明人: Pankaja K. Kadaba

    摘要: Pharmaceutical compositions comprise as the active ingredient potent orally active, nonneurotoxic anticonvulsant compounds that are excitatory amino acid and NMDA/sigma receptor antagonists and that are selected from the group consisting of those of the formulae: ##STR1## wherein R.sup.1 is 4-pyridyl or 3-pyridyl, R.sup.2 is hydrogen or methyl and R.sup.3 is 3,4-dichloro, p- or m-chloro, p-bromo, p-fluoro, p-methyl, p-methoxy or hydrogen. The compositions are administered to mammals in an amount to provide a dosage amount ranging from about 15 mg/kg to 200 mg/kg.

    摘要翻译: 药物组合物包含作为兴奋性氨基酸和NMDA /σ受体拮抗剂的有效口服活性成分的非神经毒性抗惊厥化合物,并且选自下式的那些:其中R 1是4-吡啶基或3 吡啶基,R2是氢或甲基,R3是3,4-二氯,对或间氯,对溴,对氟,对甲基,对甲氧基或氢。 将组合物以提供约15mg / kg至200mg / kg的剂量的量施用于哺乳动物。

    1-aryl-5-(2-oxo-1-pyrrolidinyl)-1,2,3-triazolines as novel
anticonvulsants
    9.
    发明授权
    1-aryl-5-(2-oxo-1-pyrrolidinyl)-1,2,3-triazolines as novel anticonvulsants 失效
    1-芳基-5-(2-氧代-1-吡咯烷基)-1,2,3-三唑啉作为新的抗惊厥药

    公开(公告)号:US4820721A

    公开(公告)日:1989-04-11

    申请号:US180163

    申请日:1988-04-11

    申请人: Pankaja K. Kadaba

    发明人: Pankaja K. Kadaba

    CPC分类号: C07D403/04

    摘要: Anticonvulsant compounds are of the formula: ##STR1## wherein R.sup.1 is 2-oxo-1-pyrrolidinyl, and R.sup.2 is hydrogen or p-chloro. They are prepared by the reaction of a phenyl azide with N-vinylpyrrolidinone.

    摘要翻译: 抗惊厥化合物具有下式:其中R 1是2-氧代-1-吡咯烷基,R 2是氢或对氯。 它们通过苯基叠氮化物与N-乙烯基吡咯烷酮的反应制备。

    Pesticidal diphenylaziridines
    10.
    发明授权
    Pesticidal diphenylaziridines 失效
    杀虫二苯基氮杂环丁烷

    公开(公告)号:US4582827A

    公开(公告)日:1986-04-15

    申请号:US529631

    申请日:1983-09-06

    CPC分类号: C07D203/08 A01N43/44

    摘要: Substituted 1,2-diphenylaziridines, particularly those which are substituted by halogen, are useful as pesticidal compositions. These 1,2-diphenylaziridines are of the following formula: ##STR1## wherein X is selected from the group consisting of hydrogen, halogen, and nitro, and Y is selected from the group consisting of hydrogen, halogen, nitro, trifluoromethyl, and lower alkyl of 1-3 carbon atoms, and n is an integer of 1 or 2, provided that when one of X and Y is hydrogen or nitro, the other is halogen.

    摘要翻译: 取代的1,2-二苯基氮丙啶,特别是被卤素取代的那些,可用作农药组合物。 这些1,2-二苯基氮丙啶具有下式:其中X选自氢,卤素和硝基,Y选自氢,卤素,硝基,三氟甲基和低级 烷基为1-3个碳原子,n为1或2的整数,条件是当X和Y中的一个为氢或硝基时,另一个为卤素。